Overview
The aim of our research is to evaluate the curative effect and safety of CyberKnife stereotactic body radiation therapy in treating small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis.
Eligibility
Inclusion Criteria:
- Primary HCC diagnosed by a surgeon and/or radiologist and oncologist according to the international guidelines for the management of HCC or by pathology
- Unfeasible or refusing to undergo other treatments;
- Residual normal liver volume ≥700 cc;
- With decompensated cirrhosis (Child-Pugh B or C classification);
- Without portal vein tumor thrombus;
- Eastern Cooperative Oncology Group (ECOG) score 0-1;
- Distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm；
- Rejecting other therapies such as resection, liver transplantation, etc.
- Platelet count≥50 × 109/L, white blood count≥1.5 × 109/L;
- Patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.
Exclusion Criteria:
- With Tumor thrombus；
- With extrahepatic metastasis;
- With lymph node involvement.